Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs TG Therapeutics Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 14× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and TG Therapeutics Inc for 16 Days on average.
| SGOV | TGTX | |
|---|---|---|
Market Cap | $114.40B | $8.16B |
Volume | 18,879,081 | 1,735,121 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $59.06 |
52-Week Low | $100.28 | $26.94 |
Typical Hold Time | 50 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV trades at $100.515 with minimal daily movement (+0.05%). The technical outlook is bearish with moving averages signaling selling pressure, though oscillators are neutral. Recent dividends of $0.30-0.31 per share were declared for H2-2026. The ETF focuses on short-term Treasury bonds, with institutional activity showing Envestnet reduced its position by 13.2% in Q2 2026.
The outlook remains cautious amid rising Treasury yields and bond market volatility. Higher interest rates could pressure short-term bond ETFs like SGOV, though they offer relative safety. Key risks include Fed policy shifts and inflation trends. Investors should weigh yield advantages against duration risk in the current rate environment.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
